BioMarin Q4 Revenue Tops Estimates, VOXZOGO Soars 31%, EPS Beats 85%
BioMarin reported Q4 revenue of $874.6M, up 17% year-on-year, beating consensus by 5.4% with net product revenues of $859.3M. EPS of $0.46 topped the $0.25 estimate by 85%, while flagship drugs saw mixed growth: VOXZOGO up 31.3% to $273M, PALYNZIQ jumped 25% to $125M and KUVAN fell 17.9% to $23M.
1. Q4 Financial Highlights
BioMarin delivered Q4 revenue of $874.6M, a 17% year-on-year rise and 5.4% above consensus, while EPS reached $0.46 versus the $0.25 estimate, marking an 85% surprise despite being down from $0.92 a year earlier.
2. Product Performance Breakdown
Net product revenues totaled $859.3M and royalty and other revenues contributed $15.2M. VOXZOGO led growth with a 31.3% rise to $273M, PALYNZIQ climbed 25% to $125M, VIMIZIM and Naglazyme rose 7.9% and 9.1% respectively, and KUVAN declined 17.9% to $23M.
3. Stock Performance and Outlook
Shares have risen 14% over the past month versus the S&P 500's 1.8% gain, and a Zacks Rank #3 (Hold) indicates the stock may track broader market performance in the near term.